JANX
Janux Therapeutics, Inc.
$16.66
-2.34%
2026-10-23
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-6.21
EPS (TTM)
$-1.64
ROE
-10.7%
Revenue Growth (YoY)
2177.9%
Profit Margin
0.0%
Debt/Equity
2.26
Price/Book
1.07
Beta
2.52
Market Cap
$996.5M
Avg Volume (10D)
1.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$20.31
60D Low
$14.86
Avg Volume
832K
Latest Close
$16.66
Get breakout alerts for JANX
Sign up for Breakout Scanner to receive daily notifications when JANX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Janux Therapeutics, Inc. (JANX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors JANX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. JANX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.